The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of trastuzumab/AT-101 combination on apoptosis and cytotoxicity in HER2-positive breast cancer cells: A novel combination to effect resistance to anti-HER2 therapy through inhibition of PI3K signaling.
Burcak Karaca
No relevant relationships to disclose
Emir Bozkurt
No relevant relationships to disclose
Harika Atmaca
No relevant relationships to disclose
Zeki Surmeli
No relevant relationships to disclose
Atike Pinar
No relevant relationships to disclose
Ulus Ali Sanli
No relevant relationships to disclose
Ruchan Uslu
No relevant relationships to disclose